ApoB Outperforms LDL for Guiding Cholesterol Therapy, New JAMA Study Finds

Originally surfaced May 13, 2026.

A May 2026 JAMA paper from Northwestern Medicine reported that, in a large simulation model, apolipoprotein B (ApoB) outperformed LDL cholesterol and non-HDL cholesterol for guiding lifetime cholesterol-lowering therapy decisions. The model concluded that an ApoB-guided strategy prevented more heart attacks and strokes over a lifetime and was cost-effective.

This is not a surprise to anyone watching the lipid field, but it is a useful data point. ApoB measures the total number of atherogenic particles in circulation. LDL cholesterol measures the cholesterol content inside one subtype of those particles. The two move together most of the time, but they diverge in clinically important ways for a meaningful share of patients, especially those with metabolic syndrome, insulin resistance, low LDL with high triglycerides, or other discordant lipid patterns.

Why ApoB matters

LDL cholesterol is a stand-in for atherogenic particle burden. ApoB measures the actual burden directly. In patients whose LDL cholesterol looks acceptable but whose ApoB is elevated, treating to LDL goal can leave real residual risk on the table.

The 2026 ACC/AHA guideline already acknowledges ApoB as a more accurate reflection of cardiovascular risk than LDL or non-HDL cholesterol in specific scenarios, including cardiovascular-kidney-metabolic syndrome, type 2 diabetes, high triglycerides, or established cardiovascular disease in patients already at LDL and non-HDL goals. An elevated ApoB, defined as 130 mg/dL or higher, is recognized as a risk-enhancing factor.

The May 2026 JAMA simulation pushes the argument further by suggesting ApoB-guided therapy outperforms LDL-guided therapy at a population level, not only in selected subgroups.

What this means for self-pay testing

LDL cholesterol is still the most common reading in a standard lipid panel and is still useful, especially for trending. ApoB is the higher-resolution alternative for anyone trying to understand cardiovascular risk in more detail.

LabTestSuperstore offers the ApoB test as a standalone. For people who want a particle-number breakdown of LDL subtypes, the NMR LipoProfile is the standard option. The lipid panel remains a reasonable baseline. The heart health panel bundles several relevant measures together. Pairing ApoB with a one-time Lp(a) test is also worth considering, because Lp(a)-associated risk is amplified when ApoB is also elevated.

For background, see our high cholesterol page and our heart disease risk page.

This article is editorial commentary and is not medical advice. Cardiovascular risk decisions should be made with a clinician who can integrate ApoB, LDL, Lp(a), blood pressure, family history, and other inputs.